Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PROOF Clear all
Terminated Phase 2 Interventional Results available

Sodium Nitroprusside in Early Course Schizophrenia

NCT04986072
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sodium Nitroprusside, 5% Dextrose solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 8:57 AM EDT
Recruiting Phase 2 Interventional

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

NCT07533019
View directory record Official record
Conditions
Vitiligo, Non-Segmental Vitiligo (NSV)
Interventions
LY4005130, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Fremont, California • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 8:57 AM EDT
Active, not recruiting Phase 1 Interventional

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

NCT05010200
View directory record Official record
Conditions
Prostate Cancer
Interventions
PGV-001, Poly-ICLC, CDX-301
Biological
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

NCT06192927
View directory record Official record
Conditions
Tennis Elbow
Interventions
TenoMiR, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Causeway Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Redwood City, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

NCT01793441
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RG7314
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 4, 2026, 8:57 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 4, 2026, 8:57 AM EDT
Completed No phase listed Observational

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1

NCT02974335
View directory record Official record
Conditions
Addiction
Interventions
Interviews with Stakeholders
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

NCT01877421
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W, 10 mg KSL-W, 20 mg KSL-W, 30 mg KSL-W, 50 mg KSL-W, 75 mg KSL-W, 100 mg KSL-W, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients

NCT04172493
View directory record Official record
Conditions
Patient
Interventions
Hyperspectral Endoscopy (HySE), White Light Endoscopy (WLE)
Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 4, 2026, 8:57 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

NCT02204371
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
View directory record Official record
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

NCT04766892
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Not applicable Interventional Results available

Proof-of-Concept Study of an Integrated Mobile and Social Network Weight Loss Intervention

NCT05295849
View directory record Official record
Conditions
Obesity
Interventions
Building Habits Together Online Weight Loss 6-Week Usability Trial
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

NCT02258152
View directory record Official record
Conditions
Parkinson's Disease Dementia (PDD)
Interventions
SYN120, Placebo
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Acamprosate in Fragile x Syndrome

NCT01911455
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 23 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional

Pramipexole and Morphine for Renal Colic

NCT04160520
View directory record Official record
Conditions
Renal Colic
Interventions
Pramipexole, Morphine, Placebo oral tablet
Drug
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 66 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD

NCT04795323
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Gastonia, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 4, 2026, 8:57 AM EDT
Enrolling by invitation Not applicable Interventional

Epidural Stimulation to Restore Voluntary Movement Following Spinal Cord Injury

NCT05966896
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
implanted epidural stimulator
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 8:57 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Efficacy of Guselkumab in Treating Hailey Hailey Disease

NCT06651489
View directory record Official record
Conditions
Hailey Hailey Disease
Interventions
Guselkumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Denture Adhesive

NCT02937870
View directory record Official record
Conditions
Denture Retention
Interventions
Test Product 1, Test Product 2, Reference Product, Negative Control
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bloomfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

NCT02655679
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
Drug · Other
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Not applicable Interventional

Investigating the Efficacy of Osteopathic Manipulative Treatment on Gait Dysfunction Following Knee Surgery

NCT05580640
View directory record Official record
Conditions
Knee Arthroscopy, Knee Arthroplasty, Osteopathic Manipulative Treatment, Gait, Unsteady
Interventions
OMT
Procedure
Lead sponsor
Midwestern University
Other
Eligibility
21 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 4, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Carbidopa-levodopa

NCT03023059
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 4, 2026, 8:57 AM EDT